TCL Archive ODAC Nixes Abraxane for Adjuvant Breast Cancer, While Genasense Falls Victim to Its Randomized Trial. September 8, 2006
TCL Archive Dasatinib, Nilotinib Show Strong Early Results As Frontline Therapy For CML December 28, 2007